These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36463731)

  • 61. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.
    Varghese AM; Arora A; Capanu M; Camacho N; Won HH; Zehir A; Gao J; Chakravarty D; Schultz N; Klimstra DS; Ladanyi M; Hyman DM; Solit DB; Berger MF; Saltz LB
    Ann Oncol; 2017 Dec; 28(12):3015-3021. PubMed ID: 29045506
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients.
    Schipper LJ; Monkhorst K; Samsom KG; Bosch LJW; Snaebjornsson P; van Boven H; Roepman P; van der Kolk LE; van Houdt WJ; van der Graaf WTA; Meijer GA; Voest EE
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053600
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type.
    Abraham J; Heimberger AB; Marshall J; Heath E; Drabick J; Helmstetter A; Xiu J; Magee D; Stafford P; Nabhan C; Antani S; Johnston C; Oberley M; Korn WM; Spetzler D
    Transl Oncol; 2021 Mar; 14(3):101016. PubMed ID: 33465745
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.
    Rassy E; Boussios S; Pavlidis N
    Eur J Clin Invest; 2021 Sep; 51(9):e13583. PubMed ID: 33970501
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study.
    Huey RW; Shah AT; Reddi HV; Dasari P; Topham JT; Hwang H; Dhillon N; Willett A; Smaglo BG; Estrella JS; Rashid A; Matamoros A; Overman MJ; Choquette L; Omerza G; Kelly K; Wang X; Loree JM; Rueter J; Varadhachary GR; Raghav K
    J Natl Cancer Inst; 2023 Aug; 115(8):994-997. PubMed ID: 37202363
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.
    Kato S; Krishnamurthy N; Banks KC; De P; Williams K; Williams C; Leyland-Jones B; Lippman SM; Lanman RB; Kurzrock R
    Cancer Res; 2017 Aug; 77(16):4238-4246. PubMed ID: 28642281
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Benefits for children with suspected cancer from routine whole-genome sequencing.
    Hodder A; Leiter SM; Kennedy J; Addy D; Ahmed M; Ajithkumar T; Allinson K; Ancliff P; Bailey S; Barnard G; Burke GAA; Burns C; Cano-Flanagan J; Chalker J; Coleman N; Cheng D; Clinch Y; Dryden C; Ghorashian S; Griffin B; Horan G; Hubank M; May P; McDerra J; Nagrecha R; Nicholson J; O'Connor D; Pavasovic V; Quaegebeur A; Rao A; Roberts T; Samarasinghe S; Stasevich I; Tadross JA; Trayers C; Trotman J; Vora A; Watkins J; Chitty LS; Bowdin S; Armstrong R; Murray MJ; Hook CE; Tarpey P; Vedi A; Bartram J; Behjati S
    Nat Med; 2024 Jul; 30(7):1905-1912. PubMed ID: 38956197
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers.
    Grewal JK; Tessier-Cloutier B; Jones M; Gakkhar S; Ma Y; Moore R; Mungall AJ; Zhao Y; Taylor MD; Gelmon K; Lim H; Renouf D; Laskin J; Marra M; Yip S; Jones SJM
    JAMA Netw Open; 2019 Apr; 2(4):e192597. PubMed ID: 31026023
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
    R Teixeira M; Oliveira J; Borralho P; O Fernandes MG; Almodovar T; Fernandes I; Macedo D; Ferreira A; Barroso A; Teixeira E; Machado JC
    Acta Med Port; 2022 Sep; 35(9):677-690. PubMed ID: 35816050
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative analysis of somatic variant calling on matched FF and FFPE WGS samples.
    de Schaetzen van Brienen L; Larmuseau M; Van der Eecken K; De Ryck F; Robbe P; Schuh A; Fostier J; Ost P; Marchal K
    BMC Med Genomics; 2020 Jul; 13(1):94. PubMed ID: 32631411
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diagnostic Yield From a Nationwide Implementation of Precision Medicine for all Children With Cancer.
    Wadensten E; Wessman S; Abel F; Diaz De Ståhl T; Tesi B; Orsmark Pietras C; Arvidsson L; Taylan F; Fransson S; Vogt H; Poluha A; Pradhananga S; Hellberg M; Lagerstedt-Robinson K; Raj Somarajan P; Samuelsson S; Orrsjö S; Maqbool K; Henning K; Strid T; Ek T; Fagman H; Olsson Bontell T; Martinsson T; Puls F; Kogner P; Wirta V; Pronk CJ; Wille J; Rosenquist R; Nistér M; Mertens F; Sabel M; Norén-Nyström U; Grillner P; Nordgren A; Ljungman G; Sandgren J; Gisselsson D;
    JCO Precis Oncol; 2023 Jun; 7():e2300039. PubMed ID: 37384868
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
    Weiss L; Heinrich K; Zhang D; Dorman K; Rühlmann K; Hasselmann K; Klauschen F; Kumbrink J; Jung A; Rudelius M; Mock A; Ormanns S; Kunz WG; Roessler D; Beyer G; Corradini S; Heinzerling L; Haas M; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8225-8234. PubMed ID: 37062035
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report.
    Mitani Y; Kanai M; Kou T; Kataoka S; Doi K; Matsubara J; Ohashi S; Matsumoto S; Muto M
    BMC Cancer; 2020 Dec; 20(1):1177. PubMed ID: 33267781
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.
    Xu Q; Chen J; Ni S; Tan C; Xu M; Dong L; Yuan L; Wang Q; Du X
    Mod Pathol; 2016 Jun; 29(6):546-56. PubMed ID: 26990976
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.
    Varadhachary GR; Spector Y; Abbruzzese JL; Rosenwald S; Wang H; Aharonov R; Carlson HR; Cohen D; Karanth S; Macinskas J; Lenzi R; Chajut A; Edmonston TB; Raber MN
    Clin Cancer Res; 2011 Jun; 17(12):4063-70. PubMed ID: 21531815
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Power and limits of modern cancer diagnostics: cancer of unknown primary.
    Hemminki K; Liu H; Heminki A; Sundquist J
    Ann Oncol; 2012 Mar; 23(3):760-764. PubMed ID: 21821544
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin.
    Liu H; Qiu C; Wang B; Bing P; Tian G; Zhang X; Ma J; He B; Yang J
    Front Cell Dev Biol; 2021; 9():619330. PubMed ID: 34012960
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study.
    van Opijnen MP; Broekman MLD; de Vos FYF; Cuppen E; van der Hoeven JJM; van Linde ME; Compter A; Beerepoot LV; van den Bent MJ; Vos MJ; Fiebrich HB; Koekkoek JAF; Hoeben A; Kho KH; Driessen CML; Jeltema HR; Robe PAJT; Maas SLN
    BMC Med Genomics; 2022 Nov; 15(1):233. PubMed ID: 36333718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.